SciSparc Ltd. (NASDAQ:SPRC) Sees Large Growth in Short Interest

SciSparc Ltd. (NASDAQ:SPRC) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 37,966 shares, an increase of 277.7% from the July 15th total of 10,052 shares. Based on an average daily trading volume, of 747,372 shares, the short-interest ratio is currently 0.1 days. Currently, 6.8% of the shares of the company are short sold.

SciSparc Stock Performance

Shares of NASDAQ:SPRC opened at $6.59 on Friday. The business has a fifty day moving average price of $6.41 and a two-hundred day moving average price of $5.85. SciSparc has a 1 year low of $2.98 and a 1 year high of $80.10.

Analyst Ratings Changes

Several research analysts have commented on SPRC shares. Weiss Ratings restated a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday, May 26th. Wall Street Zen raised shares of SciSparc to a “hold” rating in a report on Saturday, July 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.